Department of Vascular Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands.
Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Ann Surg. 2022 Dec 1;276(6):e1035-e1043. doi: 10.1097/SLA.0000000000004712. Epub 2020 Dec 23.
The goal of this study was to assess the long-term effectiveness of combination therapy for intermittent claudication, compared with supervised exercise only.
Supervised exercise therapy is recommended as first-line treatment for intermittent claudication by recent guidelines. Combining endovascular revascularization plus supervised exercise shows promising results; however, there is a lack of long-term follow-up.
The ERASE study is a multicenter randomized clinical trial, including patients between May 2010 and February 2013 with intermittent claudication. Interventions were combination of endovascular revascularization plus supervised exercise (n = 106) or supervised exercise only (n = 106). Primary endpoint was the difference in maximum walking distance at long-term follow-up. Secondary endpoints included differences in pain-free walking distance, ankle-brachial index, quality of life, progression to critical limb ischemia, and revascularization procedures during follow-up. This randomized trial report is based on a post hoc analysis of extended follow-up beyond that of the initial trial. Patients were followed up until 31 July 2017. Data were analyzed according to the intention-to-treat principle.
Median long-term follow-up was 5.4 years (IQR 4.9-5.7). Treadmill test was completed for 128/212 (60%) patients. Whereas the difference in maximum walking distance significantly favored combination therapy at 1-year follow-up, the difference at 5-year follow-up was no longer significant (53 m; 99% CI-225 to 331; P = 0.62). No difference in pain-free walking distance, ankle-brachial index, and quality of life was found during long-term follow-up. We found that supervised exercise was associated with an increased hazard of a revascularization procedure during follow-up (HR 2.50; 99% CI 1.27-4.90; P < 0.001). The total number of revascularization procedures (including randomized treatment) was lower in the exercise only group compared to that in the combination therapy group (65 vs 149).
Long-term follow up after combination therapy versus supervised exercise only, demonstrated no significant difference in walking distance or quality of life between the treatment groups. Combination therapy resulted in a lower number of revascularization procedures during follow-up but a higher total number of revascularizations including the randomized treatment.
Netherlands Trial Registry Identifier: NTR2249.
本研究旨在评估间歇性跛行的联合治疗与仅监督下运动治疗的长期疗效。
最近的指南推荐监督下运动疗法作为间歇性跛行的一线治疗方法。血管内血运重建加监督下运动治疗显示出有前景的结果;然而,缺乏长期随访。
ERASE 研究是一项多中心随机临床试验,纳入 2010 年 5 月至 2013 年 2 月间患有间歇性跛行的患者。干预措施为血管内血运重建加监督下运动治疗(n=106)或仅监督下运动治疗(n=106)。主要终点为长期随访时最大步行距离的差异。次要终点包括无痛行走距离、踝肱指数、生活质量、进展为严重肢体缺血和随访期间的血运重建程序的差异。本随机试验报告基于初始试验后延长随访的事后分析。患者随访至 2017 年 7 月 31 日。根据意向治疗原则进行数据分析。
中位长期随访时间为 5.4 年(IQR 4.9-5.7)。128/212(60%)名患者完成了跑步机测试。虽然最大步行距离的差异在 1 年随访时明显有利于联合治疗,但在 5 年随访时不再显著(53m;99%CI-225 至 331;P=0.62)。在长期随访期间,无痛行走距离、踝肱指数和生活质量没有差异。我们发现,监督下运动与随访期间血运重建程序的发生风险增加相关(HR 2.50;99%CI 1.27-4.90;P<0.001)。仅运动组的血运重建程序(包括随机治疗)总数低于联合治疗组(65 与 149)。
联合治疗与仅监督下运动治疗的长期随访显示,治疗组之间的步行距离或生活质量没有显著差异。联合治疗组在随访期间的血运重建程序数量较低,但包括随机治疗在内的血运重建总数较高。
荷兰试验注册处标识符:NTR2249。